# Diabetes and NAFLD: A Synergistic Threat to Metabolic Health

## TL;DR

This paper reviews how diabetes and nonalcoholic fatty liver disease interact and worsen each other, stressing the need for early detection and combined treatment strategies.

## Contribution

The paper proposes an integrative framework for managing diabetes and NAFLD by highlighting their pathophysiological connections and novel therapies.

## Key findings

- NAFLD and T2Dm share metabolic pathways like insulin resistance and chronic inflammation.
- Early screening and intervention are critical to prevent NAFLD progression in T2Dm patients.
- Emerging therapies aim to improve glycemic control and reduce liver fat accumulation.

## Abstract

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2Dm) are increasingly recognized as interrelated metabolic disorders, each contributing to the other’s progression. NAFLD, a leading cause of chronic liver disease globally, is often underdiagnosed due to its asymptomatic nature. The startlingly high frequency of NAFLD, especially in those with T2Dm, emphasizes the need of thorough screening in high-risk groups. In the setting of T2Dm, the pathophysiology of NAFLD comprises intricate metabolic pathways that exacerbate the disease’s progression. These pathways include insulin resistance, lipotoxicity, and chronic inflammation. Early diagnosis and timely intervention are crucial to prevent the advancement of NAFLD to more severe stages, such as nonalcoholic steatohepatitis (NASH) and cirrhosis. Current guidelines advocate for routine NAFLD screening in patients with T2Dm, emphasizing the importance of early detection. Therapeutic approaches have evolved that are pivotal in managing these intertwined conditions. Each of these treatments offers unique benefits, from improving glycemic control to mitigating liver fat accumulation and reducing cardiovascular risks. This review highlights the pathophysiological linkages, clinical implications, and therapeutic advancements in managing these conditions. By exploring global prevalence, emerging diagnostic tools, and novel therapies, we propose an integrative framework for improved patient outcomes.